ClinicalTrials.gg
RecruitingNCT07151703TOP-INUpdated Oct 5, 2026

Topical Versus Injection PRP for Olfactory Dysfunction

A Phase 3 interventional study of Intranasal Injection of Autologous PRP and Carrier-Assisted Topical Application of Autologous PRP in Olfactory Dysfunction, Anosmia and Hyposmia, sponsored by Taipei Veterans General Hospital, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Taipei Veterans General Hospital, Taiwan · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 5, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than three months. The main questions it aims to answer are:

  1. Does carrier-assisted topical application of PRP lead to comparable or better improvement in smell function than intranasal injection of PRP?
  2. Which method provides greater patient comfort and fewer adverse effects?

Researchers will compare carrier-assisted topical PRP application to intranasal PRP injection to see if one approach is more effective in restoring olfactory function.

Participants will:

  1. Receive a single PRP treatment delivered either by injection or via a PRP-soaked carrier placed into the olfactory cleft.
  2. Continue daily olfactory training for three months following the intervention.
  3. Undergo smell testing (Sniffin' Sticks) before and after treatment and complete quality-of-life questionnaires.
Read the detailed description

Persistent olfactory dysfunction (OD) is a common sequela of viral upper respiratory tract infections, including COVID-19, and can significantly affect patients' quality of life, nutrition, and safety. Current treatment options are limited, with olfactory training being the primary evidence-based non-pharmacological therapy. Autologous platelet-rich plasma (PRP) is a concentration of platelets obtained from a patient's own blood, rich in growth factors and cytokines that promote neuronal regeneration, tissue repair, and neuroplasticity. Early clinical studies suggest PRP may improve olfactory function, but the optimal method for delivering PRP to the olfactory cleft remains unknown.

This randomized controlled trial will include a total of 60 adult patients aged 18-80 years old with olfactory loss (hyposmia or anosmia) persisting for more than 3 months despite standardized olfactory training, confirmed by a reduced Sniffin' Sticks TDI score.

PRP will be prepared on-site immediately before application using a standardized centrifugation protocol to achieve a platelet concentration 2-3 times above baseline. efficacy and safety of two PRP delivery methods will be compared:

Intranasal Injection Group: Autologous PRP will be injected directly into the mucosa of the olfactory cleft under endoscopic guidance. After topical anesthesia with lidocaine spray and decongestion with oxymetazoline, a 25-gauge needle will be used to deliver approximately 1 mL of PRP into multiple sites along the superior nasal cavity bilaterally.

Carrier-Assisted Topical Application Group: Four pieces of sterile, bioabsorbable carrier (Gelfoam sponge) will be soaked with approximately 5 mL of autologous PRP. Under endoscopic guidance, two pieces of PRP-soaked carrier will be placed gently into each side of olfactory cleft, ensuring contact with the olfactory mucosa. Carriers will remain in place for a short duration to allow diffusion of PRP before dissolving naturally or being removed.

Primary Outcome: Change in TDI score from baseline to 3 months post-treatment.

Secondary Outcomes: Patient-reported olfactory-related quality of life (QOD, SNOT-22, PQ), subjective improvement ratings, 20-item retronasal olfactory test, SSParoT, procedure tolerability, and adverse event rates.

Post-intervention care: All participants will continue standardized daily olfactory training for at least 12 weeks after PRP administration. Follow-up visits at 2 weeks, 1 month and 3 months will assess smell function, symptom changes, and safety.

This study aims to determine whether carrier-assisted topical PRP application is as effective or superior to intranasal PRP injection for improving olfactory function, while potentially offering a less invasive and more tolerable treatment approach. Results will help define optimal PRP delivery strategies for olfactory rehabilitation in clinical practice.

02

Conditions studied

  • Olfactory Dysfunction
  • Anosmia
  • Hyposmia

Browse trials for

Keywords

  • Anosmia
  • Hyposmia
  • Platelet-Rich Plasma (PRP)
  • Intranasal Injection
  • Randomized Controlled Trial
03

In context

Anosmia

180 studies on the registry are indexed under Anosmia; 45 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 114 interventional studies indexed under Anosmia.

Browse Anosmia studies →

Lead sponsor

Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 80 years, regardless of sex
  • Subjective complaint of olfactory dysfunction with confirmed hyposmia or anosmia based on standardized olfactory testing
  • History of at least 3 months of prior olfactory training but with persistent olfactory complaints

Exclusion criteria

Exclusion Criteria:

  • Congenital anosmia
  • Diagnosed neurological or structural brain abnormalities (e.g., brain tumor, major head trauma, stroke) with low likelihood of olfactory recovery
  • Inability or unwillingness to comply with study procedures or follow-up assessments
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intranasal PRP injection

    Participants in this arm will receive an intranasal injection of autologous platelet-rich plasma (PRP) into the olfactory cleft. The procedure will be conducted under local anesthesia using endoscopic guidance. All participants will also perform standardized daily olfactory training for three months following the intervention.

    Procedure: Intranasal Injection of Autologous PRP · Combination Product: platelet-rich plasma · Device: olfactory training

  • Experimental
    Topical PRP application arm

    Participants in this arm will receive a topical application of autologous PRP delivered via PRP-soaked absorbable material (Gelfoam) placed into the olfactory cleft. No needle will be used. The placement will be guided by nasal endoscopy under local anesthesia. Daily olfactory training will be continued for three months post-application.

    Procedure: Carrier-Assisted Topical Application of Autologous PRP · Combination Product: platelet-rich plasma · Device: olfactory training

Interventions

  • ProcedureIntranasal Injection of Autologous PRP

    Under topical anesthesia and decongestion, approximately 1 mL of freshly prepared autologous platelet-rich plasma will be injected into multiple sites of the olfactory cleft mucosa bilaterally using a 25-gauge needle under endoscopic guidance. Single treatment session.

  • ProcedureCarrier-Assisted Topical Application of Autologous PRP

    Four pieces of sterile, bioabsorbable carrier (Gelfoam sponge) will be soaked with approximately 5 mL of freshly prepared autologous platelet-rich plasma. Under endoscopic guidance, two pieces will be placed gently into each olfactory cleft, ensuring contact with the olfactory mucosa. Carriers will remain briefly to allow PRP diffusion before dissolving naturally or being removed. Single treatment session.

  • Combination productplatelet-rich plasma

    This study adopts a fully automated, closed-system PRP preparation technique to ensure the stability of the blood product. A total of 60 mL of whole blood is drawn and processed using the Phoenix Q1 centrifuge (TFDA Medical Device Manufacturing License No. 004461) for blood component separation in a closed, sterile environment. An optical sensor identifies and automatically collects the buffy coat layer (rich in platelets and monocytes), yielding approximately 6 mL of autologous platelet-rich plasma (PRP). The centrifugation and PRP collection process takes about 5 minutes. Compared with traditional methods requiring manual identification and collection, this approach enhances the precision and safety of centrifugation-based preparation.

  • Deviceolfactory training

    Participants will perform olfactory training for 12 weeks following the PRP intervention. Training is conducted twice daily using four odor bottles containing standardized odorants from Sigma-Aldrich (Germany): lemon (citronellal, #27470), rose (phenylethanol, #77861), clove (eugenol, #W246700), and eucalyptus (eucalyptol, #C80601). Each odor is sniffed gently for about 20 seconds, with a 20-second pause between bottles. Participants will record the perceived intensity of each odor in a training diary after every session.

06

What researchers measure

Primary outcomes

  1. Sniffin' Sticks Olfactory Test

    The Sniffin' Sticks test (Burghart Messtechnik GmbH, Holm, Germany) comprises three subtests for odor detection threshold (T), odor discrimination (D), and odor identification (I). This test employs odor-containing felt-tip pens, which are presented to participants to evaluate their olfactory performance. In the detection threshold subtest, we employed an adaptive staircase procedure based on a three-alternative forced-choice format. Participants were tasked with differentiating a stick with a rose-like aroma (phenylethyl alcohol) from two blank sticks. Odor discrimination was assessed using 16 pen triplets, two of which contained identical odors and one stick contained a different odor. Participants were tasked with identifying the odd one out. In the odor identification subtest, participants were tasked with naming 16 common odors by selecting appropriate terms from a set of four descriptors per odor. The scores from each subtest were combined into a composite TDI score.

    Time frame: pre-intervention and at 1 and 3 months (may extend to 6 and 12 months) post-intervention

Secondary outcomes

  1. Procedure-related pain evaluation

    Visual analogue scale for pain (0-10) immediately after procedure.

    Time frame: during the procedure and up to 2 weeks post-intervention

  2. Retronasal Olfactory Test

    Retronasal olfactory testing was performed using standardized odorized powders/capsules presented in the oral cavity, with participants instructed to exhale through the nose and rate the perceived odor. It specifically evaluates olfactory function via the retronasal route.

    Time frame: pre-intervention and at 3 months post-intervention

  3. Visual Analogus Scale for olfaction

    Visual Analogus Scale for olfactory function from 0 to 10. (0 means inability of smelling and 10 means super good smell function)

    Time frame: pre-intervention and at 1 and 3 months (may extend to 6 and 12 months) post-intervention

  4. Questionnaire of Olfactory Disorders (QOD)

    A questionnaire on olfaction-related quality of life status

    Time frame: pre-intervention and at 1 and 3 months (may extend to 6 and 12 months) post-intervention

  5. Beck Depression Inventory (BDI)

    The Beck Depression Inventory (BDI) is a standardized self-report questionnaire measuring the severity of depressive symptoms. Olfactory loss, resulting from viral infections or other etiologies, has been associated with mood disturbances and reduced emotional well-being.

    Time frame: pre-intervention and 3 months post-intervention

  6. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is a widely used screening tool for mild cognitive impairment. Olfactory loss has been shown to diminish sensory stimulation to the brain, potentially affecting neural processing and cognitive function.

    Time frame: pre-intervention and post-3 month intervention

  7. 22-item Sinonasal Outcome Test (SNOT-22)

    A questionaire reflecting the severity of symptoms and the impact of sinonasal diseases

    Time frame: pre-intervention and at 1 and 3 months (may extend to 6 and 12 months) post-intervention

  8. Parosmia Questionnaire (PQ)

    A 4-item questionnaire to evaluate the presence, severity, and qualitative characteristics of odor distortions (parosmia).

    Time frame: pre-intervention and at 1 and 3 months (may extend to 6 and 12 months) post-intervention

  9. Sniffin' Sticks Parosmia Test

    SSParoT (Sniffin' Sticks Parosmia Test) is a specialized assessment tool to evaluate qualitative olfactory function, particularly for the objective quantification of parosmia. It presents a series of well-characterized odorants and asks participants to rate each odor's pleasantness. From these ratings, the range of hedonic ratings and the hedonic orientation are calculated, providing quantitative measures of the breadth and direction of the participant's odor preference profile. This approach enables clinicians to identify patterns of altered odor perception and monitor changes following therapeutic interventions. The SSParoT (Sniffin' Sticks Parosmia Test) was additionally administered to participants with parosmia to calculate the range of hedonic ratings and the hedonic orientation.

    Time frame: pre-intervention and 3 months post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bae AY, Kim DH, Hwang SH. Efficacy of Platelet-Rich Plasma in the Treatment of Persistent Olfactory Impairment After COVID-19: A Systematic Review and Meta-Analysis. J Rhinol. 2024 Mar;31(1):1-7. doi: 10.18787/jr.2024.00006. Epub 2024 Mar 31. PubMed 39664044 ↗
  • Duffy A, Naimi B, Garvey E, Hunter S, Kumar A, Kahn C, Farquhar D, D'Souza G, Rawson N, Dalton P, Toskala E, Rabinowitz M, Rosen M, Nyquist G, Rosen D. Topical platelet-rich plasma as a possible treatment for olfactory dysfunction-A randomized controlled trial. Int Forum Allergy Rhinol. 2024 Sep;14(9):1455-1464. doi: 10.1002/alr.23363. Epub 2024 May 9. PubMed 38722276 ↗
  • Jiang RS, Chiang YF. The Effect of Platelet-Rich Plasma and Hyaluronic Acid Nasal Injections in the Treatment of Traumatic Olfactory Dysfunction. Ear Nose Throat J. 2024 Oct 15:1455613241291710. doi: 10.1177/01455613241291710. Online ahead of print. PubMed 39404838 ↗
  • Lechien JR, Le Bon SD, Saussez S. Platelet-rich plasma injection in the olfactory clefts of COVID-19 patients with long-term olfactory dysfunction. Eur Arch Otorhinolaryngol. 2023 May;280(5):2351-2358. doi: 10.1007/s00405-022-07788-8. Epub 2022 Dec 15. PubMed 36520209 ↗
  • Yan CH, Mundy DC, Patel ZM. The use of platelet-rich plasma in treatment of olfactory dysfunction: A pilot study. Laryngoscope Investig Otolaryngol. 2020 Feb 21;5(2):187-193. doi: 10.1002/lio2.357. eCollection 2020 Apr. PubMed 32337347 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — The decision regarding IPD sharing will be made upon completion of the study, pending institutional policies and ethical review board recommendations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Sep 2025, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2025
First posted
Sep 3, 2025
StartActual
Sep 11, 2025was Oct 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
Taipei Veterans General Hospital is now Recruiting
Oct 5, 2026
Start date
Oct 1, 2025→Sep 11, 2025 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    Taipei Veterans General Hospital is now Recruiting
    Start date Oct 1, 2025→Sep 11, 2025 (now actual)
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07151703
Responsible party
Yun-Ting Chao (Director of Rhinology Division, Taipei Veterans General Hospital, Taiwan) — Principal investigator
First posted
Sep 3, 2025
Start date
Sep 11, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Dr. Yun-Ting Chao Principal Investigator (Attending Physician and Head of Dep.), PhD
Contact
yunting001@gmail.com
886-2-2875-7337 ext. 122

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion